Alzheimer

IGC Pharma Inc (NYSE:IGC) witnessed a surge of 69.40%  in its stock value during after-hours trading on Wednesday. What Happened: The stock of IGC Pharma, a company involved in the development of cannabinoid-based therapies for Alzheimer‘s disease, rose by 69.40% to $0.62. This surge...

Tesla and SpaceX CEO Elon Musk has hinted at the possibility of his brain-machine interface company, Neuralink, developing an implant for early-stage Alzheimer’s disease. What Happened: Sharing a clip from his appearance at the 2024 Congress of Neurological Surgeons last month, Musk took...

A recent study has found that dronabinol, a synthetic version of THC (the primary psychoactive component in cannabis), effectively reduces agitation in Alzheimer's patients. Presented at the International Psychogeriatric Association conference in Buenos Aires, Argentina, the study reveals that...

The Wall Street Journal reported that the SEC had launched a probe into claims that Cassava Sciences Inc (NASDAQ: SAVA) manipulated data key to its case for its experimental Alzheimer’s drug simufilam. The report comes just two days after Cassava, in an SEC filing,...

Cyclo Therapeutics Inc (NASDAQ: CYTH) has submitted its initial investigational new drug (IND) application with the FDA for a Phase 2 study of Trappsol Cyclo for early Alzheimer's Disease (AD). Related Link: Cyclo Therapeutics' Trappsol Shows Early Safety, Efficacy In...

Screen capture via IGC's healthcare subsidiary Hyalolex. "Drops of Clarity" is their just-patented Alzheimer's treatment. Two Stocks Spike On Alzheimer's News With six million Americans suffering from Alzheimer's disease, their loved ones are desperate for...

Alzheimer's has proven to be one of the most stubborn diseases known to modern medicine. An incurable, devastating illness that inspires frustration — even anger — against and from the scientific community itself, which has failed to develop new, effective therapies. Susanne...

JPMorgan has upgraded Eli Lilly and Co (NYSE: LLY) to Overweight from Neutral based on the potential for new product driven upside to estimates in 2017 and beyond. The brokerage's bullish thesis also reflects a favorable risk/reward for solanezumab data in Alzheimer patients late this year. Notably...